AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalData EP News Bureau Apr 25, 2024 Most of Lynparza’s sales come from ovarian and HER2-negative breast cancer treatment
Zydus launches IBYRA, the generic version of Olaparib EP News Bureau Mar 13, 2024 The drug will target specific genetic mutations prevalent in certain types of cancers
